| 000 | 01548 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250516150948.0 | ||
| 264 | 0 | _c20140324 | |
| 008 | 201403s 0 0 eng d | ||
| 022 | _a1434-9949 | ||
| 024 | 7 |
_a10.1007/s10067-013-2272-9 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAlvarez-Lario, Bonifacio | |
| 245 | 0 | 0 |
_aSevere Guillain-Barré syndrome in a patient receiving anti-TNF therapy. Consequence or coincidence. A case-based review. _h[electronic resource] |
| 260 |
_bClinical rheumatology _cSep 2013 |
||
| 300 |
_a1407-12 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article; Review | ||
| 650 | 0 | 4 | _aAdalimumab |
| 650 | 0 | 4 |
_aAdrenal Cortex Hormones _xtherapeutic use |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadministration & dosage |
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _xcomplications |
| 650 | 0 | 4 | _aCampylobacter Infections |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGuillain-Barre Syndrome _xcomplications |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulins, Intravenous _xtherapeutic use |
| 650 | 0 | 4 |
_aMethotrexate _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRespiration, Artificial |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 700 | 1 | _aPrieto-Tejedo, Rosa | |
| 700 | 1 | _aColazo-Burlato, María | |
| 700 | 1 | _aMacarrón-Vicente, Jesús | |
| 773 | 0 |
_tClinical rheumatology _gvol. 32 _gno. 9 _gp. 1407-12 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10067-013-2272-9 _zAvailable from publisher's website |
| 999 |
_c22743897 _d22743897 |
||